空气传播 发表于 2025-3-25 05:21:34

Infliximab: From the Idea to the Productle and membrane- bound TNF-α . Infliximab does not bind to TNF-β (lymphotoxin α ), a related cytokine that utilizes the same receptors as TNF-α. Thus infliximab was developed as a therapeutic agent for various inflammatory chronic diseases that are believed to be driven by the pro-inflammatory cytokine TNF-α.

ectropion 发表于 2025-3-25 08:55:07

http://reply.papertrans.cn/19/1876/187535/187535_22.png

BOLT 发表于 2025-3-25 14:46:42

Biologics in Cutaneous Lymphomatracutaneous disease at the time of diagnosis. They can be distinguished into cutaneous T-cell lymphomas (CTCL), cutaneous B-cell lymphomas (CBCL) and the rare precursor dendritic cell neoplasms. The PCL are now classified in the new WHO-EORTC classification (.; Table 14.1).

–LOUS 发表于 2025-3-25 15:51:15

http://reply.papertrans.cn/19/1876/187535/187535_24.png

遗留之物 发表于 2025-3-25 23:27:31

http://reply.papertrans.cn/19/1876/187535/187535_25.png

多山 发表于 2025-3-26 01:01:56

http://reply.papertrans.cn/19/1876/187535/187535_26.png

alleviate 发表于 2025-3-26 05:30:39

Claire R. McInerney,Michael E. D. Koenigtem. Examples include antibodies directed against very specific molecular components of the immune response, for example, pro-inflammatory cytokines, or naturally occurring cytokine inhibitors such as IL-1 receptor antagonist (IL-1ra).

用树皮 发表于 2025-3-26 11:09:56

http://reply.papertrans.cn/19/1876/187535/187535_28.png

小说 发表于 2025-3-26 14:23:41

https://doi.org/10.1007/978-3-319-03698-4n overreactive immune system. Carrier substances that falsely inform the body about an ongoing infection are produced in large quantities. The immune system answers by starting a strong immune response. The body’s own tissues are attacked and continuously destroyed. Specific models of reaction have

玩忽职守 发表于 2025-3-26 18:52:20

Springer Texts in Business and Economicsle and membrane- bound TNF-α . Infliximab does not bind to TNF-β (lymphotoxin α ), a related cytokine that utilizes the same receptors as TNF-α. Thus infliximab was developed as a therapeutic agent for various inflammatory chronic diseases that are believed to be driven by the pro-inflammatory cytok
页: 1 2 [3] 4 5 6
查看完整版本: Titlebook: Biologics in General Medicine; Wolf-Henning Boehncke,Heinfried H. Radeke Book 2007 Springer-Verlag Berlin Heidelberg 2007 Arthritis.Monito